公开(公告)号：WO2022238963A2

公开(公告)日：2022-11-17

申请号：PCT/IB2022/054447

申请日：2022-05-12

申请人： CRISPR THERAPEUTICS AG

发明人： TERRETT, Jonathan Alexander ,  DEQUEANT, Mary-Lee ,  WILL, Matthias

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C12N15/113 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/828 ,  A61K2039/852 ,  A61K2039/86 ,  A61K2039/868 ,  A61K2039/892 ,  A61K35/17 ,  A61K39/001138 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2319/03 ,  C12N15/1138 ,  C12N15/625 ,  C12N2310/20 ,  C12N5/0636

摘要： A method for treating a solid tumor (e.g., a CD70+ solid tumor) comprising one or more cycles of treatment, each cycle comprising administering to a human patient in need thereof an effective amount of a population of genetically engineered T cells after a lymphodepleting therapy, and optionally a treatment comprising an anti-CD38 antibody. The population of genetically engineered T cells comprises T cells expressing a chimeric antigen receptor (CAR) that binds CD70.

公开(公告)号：WO2022221726A2

公开(公告)日：2022-10-20

申请号：PCT/US2022/025115

申请日：2022-04-15

申请人： JUNO THERAPEUTICS, INC. ,  CELGENE CORPORATION

发明人： RYTLEWSKI, Julie Ann ,  PITTARI, Gianfranco

IPC分类号： A61K31/5377 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K31/573 ,  A61K39/001117 ,  C07K14/7051 ,  C07K2319/03

摘要： Provided herein are methods, compositions, and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA). In some aspects, the present disclosure relates to certain combination therapies that include administration of a cell therapy, such as a BCMA-targeted T cell therapy, in combination with immunomodulatory agents and other agents, such as dexamethasone, including for the treatment of subjects with multiple myeloma. In some embodiments, the multiple myeloma is a relapsed or refractory multiple myeloma.

公开(公告)号：WO2022146891A2

公开(公告)日：2022-07-07

申请号：PCT/US2021/065157

申请日：2021-12-23

申请人： SANA BIOTECHNOLOGY, INC. ,  FRY, Terry, J.

发明人： SCHREPFER, Sonja ,  WENG, Lindong

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/804 ,  A61K39/001112 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2803 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N5/0636

摘要： Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

公开(公告)号：WO2021245071A1

公开(公告)日：2021-12-09

申请号：PCT/EP2021/064659

申请日：2021-06-01

申请人： MV BIOTHERAPEUTICS SA

发明人： GRASSI, Fabio

IPC分类号： C12N9/16 ,  A61P37/02 ,  C12N15/113 ,  A61K39/39 ,  A61K39/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55516 ,  A61K39/0011 ,  A61K39/395 ,  C07K16/2827 ,  C07K2317/76

摘要： The present invention provides a combination of (i) an immune checkpoint modulator and (ii) an ATP hydrolyzing enzyme, a nucleic acid encoding an ATP hydrolyzing enzyme, or host cells, microorganisms or viral particles comprising such nucleic acids encoding an ATP hydrolyzing enzyme. The combination may be used in medicine, in particular in the treatment of cancer, for example in cancer immunotherapy.

公开(公告)号：WO2021197391A1

公开(公告)日：2021-10-07

申请号：PCT/CN2021/084655

申请日：2021-03-31

申请人： 苏州克睿基因生物科技有限公司

发明人： 王文博 ,  冯爱华 ,  郭佩佩 ,  林彦妮

IPC分类号： C12N15/90 ,  C12N9/22 ,  C12N5/10 ,  A61K39/00 ,  A61P35/00 ,  A61P35/02 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K39/001111 ,  C07K14/7051 ,  C07K16/2875 ,  C07K2317/622 ,  C07K2319/00 ,  C12N15/907 ,  C12N2510/00

摘要： 提供了一种制备经修饰的免疫细胞的方法，包括向免疫细胞施用靶向编码CD70的核酸分子的指导RNA，还提供了所述方法得到的CD70敲除的免疫细胞，以及包含该免疫细胞的细胞群和药物组合物，并提供了一种包括指导RNA和Cas蛋白的CRISPR/Cas系统。

公开(公告)号：WO2021167418A2

公开(公告)日：2021-08-26

申请号：PCT/KR2021/002157

申请日：2021-02-19

申请人： 서울대학교 산학협력단

发明人： 성승용 ,  박현미 ,  백범서

IPC分类号： A61K39/00 ,  A61K47/64 ,  A61K35/17 ,  A61P35/00 ,  C07K14/47 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/6031 ,  A61K39/0011 ,  A61K47/646 ,  C07K14/4748 ,  C07K2319/00

摘要： 본 발명은 신규한 종양-관련 항원(tumor-associated antigen) 단백질 OLFM4(olfactomedin 4) 및 이의 용도에 관한 것으로, 구체적으로 OLFM4 또는 ANTP(antennapedia peptide)-접합된 OLFM4 재조합 단백질이 탑재된 수지상세포가 종양 특이적 세포독성 면역반응을 유도하는 것을 확인하였으므로, 상기 OLFM4를 종양-관련 항원 단백질로서, 상기 종양-관련 항원 단백질이 탑재된 항원-제시 세포 또는 상시 항원-제시 세포로부터 유도된 세포독성 T 림프구를 암의 면역치료에 유용하게 이용할 수 있다.

公开(公告)号：WO2021119293A2

公开(公告)日：2021-06-17

申请号：PCT/US2020/064286

申请日：2020-12-10

申请人： CHILDREN'S NATIONAL MEDICAL CENTER

发明人： HARRIS, Katherine ,  KELLER, Michael ,  BOLLARD, Catherine

IPC分类号： A61K39/145 ,  A61K39/39 ,  C12N7/00 ,  A61K2039/5158 ,  A61K39/12 ,  C12N2760/18634 ,  C12N2760/18671

摘要： Disclosed are compositions of T-cells, libraries of such T-cells, and methods of making T-cell subpopulations for treatment of human parainfluenza virus (HPIV) infections, particularly HPIV type 3 (HPIV3) infections. Also disclosed are T-cell compositions comprising cell subpopulations stimulated with HPIV3 antigens and T cell banks containing these compositions for off-the-shelf availability of T cells for treatment of disease.

公开(公告)号：WO2021040736A1

公开(公告)日：2021-03-04

申请号：PCT/US2019/049099

申请日：2019-08-30

申请人： OBSIDIAN THERAPEUTICS, INC.

发明人： SURI, Vipin ,  BRISKIN, Michael Joseph ,  DOLINSKI, Brian ,  ELPEK, Kutlu, Goksu ,  EZELL, Tucker ,  HELLER, Scott Francis ,  INNISS, Mara, Christine ,  KASSUM, Tariq A. ,  KOSMIDER, Nicole ,  KULKARNI, Abhishek ,  LANGLEY, Meghan ,  LI, Dan Jun ,  OLS, Michelle Lynn ,  PRIMACK, Benjamin J. ,  RICHARDSON, Celeste ,  SHAMAH, Steven Mark ,  STORER, James ,  SUN, Dexue ,  BALAKRISHNAN, Vijaya ,  BRADBURY, Andrew R. M. ,  ERASMUS, Michael Frank ,  FERRARA, Fortunato

IPC分类号： A61K38/17 ,  C07K14/52 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N9/06 ,  C12N9/90 ,  C12N5/0783 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K35/17 ,  A61K38/00 ,  A61K39/001112 ,  A61P35/00 ,  C07K14/5434 ,  C07K14/5443 ,  C07K16/2803 ,  C07K2317/70 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/0636 ,  C12N9/003 ,  C12Y105/01003 ,  C12Y502/01008

摘要： The present invention provides biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.

公开(公告)号：WO2023000685A1

公开(公告)日：2023-01-26

申请号：PCT/CN2022/079966

申请日：2022-03-09

申请人： 卡瑞济（北京）生命科技有限公司

发明人： 钟晓松 ,  张莹

IPC分类号： C12N15/85 ,  C12N15/62 ,  C12N15/12 ,  C12N5/10 ,  A61K39/00 ,  A61K38/20 ,  A61P35/00 ,  A61P35/02 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/585 ,  A61K38/2086 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/7051 ,  C07K16/2803 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2510/00 ,  C12N5/0636 ,  C12N5/0646

摘要： 提供了一种增加Survivin表达的CAR-T细胞及其单独或联合IL-15在制备抗肿瘤药物中的应用。

公开(公告)号：WO2023275402A1

公开(公告)日：2023-01-05

申请号：PCT/EP2022/068416

申请日：2022-07-04

申请人： UNIVERSITAT DE BARCELONA ,  HOSPITAL CLÍNIC DE BARCELONA ,  INSTITUT D’INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS)

发明人： LOZANO SOTO, Francisco ,  VELASCO DE ANDRÉS, María

IPC分类号： C07K14/725 ,  A61K35/17 ,  C07K14/47 ,  C07K14/705 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K39/0005 ,  C07K14/4702 ,  C07K14/7051 ,  C07K14/70596 ,  C07K2319/00 ,  C07K2319/33

摘要： The present invention refers to the medical field. Particularly, the present invention refers to autologous/allogeneic CAR (chimeric antigen receptor)-T/NK cells for use in the treatment of invasive fungal infections.